Asthma is a significant research concept in respiratory science and clinical medicine dedicated to the systematic investigation of a chronic inflammatory disease of the airways. It explores its complex pathophysiology, diverse clinical presentations, diagnosis, treatment, and public health impact.
Ontological type
Pathophysiology
Therapeutic Strategies
Phenotypes and Endotypes
Immuno-Structural Foundations
1927 - 1991
Biomarker and Endotype Emergence
1992 - 2010
Precision Type 2 Biologics
2011 - 2024
Immuno-Structural Foundations era
Richard Beasley [1] is a prominent asthma researcher whose work in this era integrated clinical inquiry with airway structural pathology, with affiliations including New York University [2] and University of Otago [3]. His key contributions in this era include the identification of subepithelial fibrosis as a remodeling feature in asthmatic bronchi, highlighted in the 1989 paper SUBEPITHELIAL FIBROSIS IN THE BRONCHI OF ASTHMATICS [4], which reframed asthma as a disease of both inflammation and structural change driving obstruction. Beasley [1] further helped reshape the field by framing asthma as a syndrome of coupled inflammatory and remodeling processes relevant to diagnosis and management in this era. Building on the 1989 work [4], his findings underscored the value of physiologic measurement and targeted inhaled therapies to interrogate and modulate airway remodeling in asthma.
Biomarker and Endotype Emergence era
Neil Pearce [1], associated with the University of Washington [3] and the University of Pittsburgh [4], was a key figure in asthma epidemiology during the Biomarker and Endotype Emergence era. His pivotal contribution was co-authoring the International Study of Asthma and Allergies in Childhood (ISAAC) rationale and methods [7], which standardized multicenter epidemiology and enabled cross-population comparisons essential for biomarker-driven phenotyping in this era. Richard Beasley [2], affiliated with Imperial College London [5] and McMaster University [6], was active in asthma research during the same era. Beasley contributed as a co-author of ISAAC [7], helping build international consensus and methodological standardization that supported biomarker-guided endotyping and translational pathways for interventional trials in asthma.
Precision Type 2 Biologics era
Kian Fan Chung [1] is a leading asthma researcher associated with Harvard University [3] and the University of California, San Francisco [4] during the Precision Type 2 Biologics era. His key contributions in this era center on the 2013 International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma [7], which standardized criteria and management and informed trial design for precision therapies. Andrew Bush [2] is a prominent figure associated with Duke University [5] and University College London [6] during this era. His contributions include the 2013 International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma [7], which, beyond standardizing definitions, supported phenotype-guided, mechanism-based management and underpinned integration of biologics into stratified care pathways.